Delaware
|
11-3516358
|
|||
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
37000 Grand River
Avenue, Suite 120
Farmington Hills, MI
|
48335
|
|||
(Address of principal executive offices)
|
(Zip code)
|
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan
|
(Full title of the plan)
|
Mina Sooch
President and Chief Executive Officer
Ocuphire Pharma, Inc.
37000 Grand River Avenue, Suite 120
Farmington Hills, MI 48335
(248) 681-9815
|
(Name, address, and telephone number, including area code, of agent for service)
|
Item 3. | Incorporation of Documents By Reference. |
(a) |
the Registrant’s Annual Report on Form 10-K filed on March 24, 2022;
|
(b) |
the Registrant’s Current Reports on Form 8-K filed on January 31, 2022 and March 29, 2022; and
|
(c) |
the description of the Company’s Common Stock contained in the Company’s Form 8-A (File No. 001-34079), as filed with
the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on May 23, 2008.
|
Item 8. | Exhibits. |
Exhibit
Number
|
Description
|
|
Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix G to the Company’s Definitive Proxy Statement on Schedule
14A filed on April 29, 2005)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K, filed on May 5, 2017)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K, filed on August 30, 2018)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K, filed on April 12, 2019).
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current
Report on Form 8-K, filed on November 6, 2020)
|
||
Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Current
Report on Form 8-K, filed on November 6, 2020)
|
||
Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K, filed
on November 6, 2020)
|
||
Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Company’s Registration Statement on Form S-4, filed
on September 30, 2020)
|
||
Opinion of Honigman LLP
|
||
Consent of Ernst & Young LLP
|
||
23.2 |
Consent of Honigman LLP (included in Exhibit 5.1)
|
|
Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
|
||
Filing Fee Table
|
OCUPHIRE PHARMA, INC.
|
|||
By:
|
/s/ Mina Sooch
|
||
Name:
|
Mina Sooch
|
||
Title:
|
President and Chief Executive Officer
|
SIGNATURE
|
TITLE
|
DATE
|
||
/s/ Mina Sooch
|
||||
Mina Sooch
|
President, Chief Executive Officer & Director
(Principal Executive Officer)
|
April 5, 2022
|
||
/s/ Amy Rabourn | ||||
Amy Rabourn
|
Vice President of Finance
(Principal Financial and Accounting Officer)
|
April 5, 2022
|
||
/s/ Sean Ainsworth |
|
|
||
Sean Ainsworth
|
Director |
April 5, 2022
|
||
/s/ James S. Manuso | ||||
James S. Manuso
|
Director
|
April 5, 2022
|
||
/s/ Cam Gallagher
|
|
|
||
Cam Gallagher
|
Director
|
April 5, 2022
|
||
/s/ Jay Pepose
|
||||
Jay Pepose
|
Director
|
April 5, 2022
|
/s/ Richard J. Rodgers
|
|
|
||
Richard J. Rodgers
|
Director
|
April 5, 2022 | ||
/s/ Susan K. Benton
|
|
|||
Susan K. Benton
|
Director
|
April 5, 2022
|